1. Home
  2. RGNX vs GILT Comparison

RGNX vs GILT Comparison

Compare RGNX & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGNX
  • GILT
  • Stock Information
  • Founded
  • RGNX 2008
  • GILT 1987
  • Country
  • RGNX United States
  • GILT Israel
  • Employees
  • RGNX N/A
  • GILT N/A
  • Industry
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • GILT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • RGNX Health Care
  • GILT Technology
  • Exchange
  • RGNX Nasdaq
  • GILT Nasdaq
  • Market Cap
  • RGNX 387.0M
  • GILT 381.2M
  • IPO Year
  • RGNX 2015
  • GILT 1993
  • Fundamental
  • Price
  • RGNX $9.49
  • GILT $5.91
  • Analyst Decision
  • RGNX Strong Buy
  • GILT Strong Buy
  • Analyst Count
  • RGNX 8
  • GILT 2
  • Target Price
  • RGNX $31.75
  • GILT $8.50
  • AVG Volume (30 Days)
  • RGNX 1.3M
  • GILT 466.1K
  • Earning Date
  • RGNX 07-31-2025
  • GILT 05-19-2025
  • Dividend Yield
  • RGNX N/A
  • GILT N/A
  • EPS Growth
  • RGNX N/A
  • GILT N/A
  • EPS
  • RGNX N/A
  • GILT 0.24
  • Revenue
  • RGNX $156,718,000.00
  • GILT $321,407,000.00
  • Revenue This Year
  • RGNX $313.52
  • GILT $42.88
  • Revenue Next Year
  • RGNX N/A
  • GILT $13.26
  • P/E Ratio
  • RGNX N/A
  • GILT $24.92
  • Revenue Growth
  • RGNX 80.70
  • GILT 13.49
  • 52 Week Low
  • RGNX $5.04
  • GILT $4.04
  • 52 Week High
  • RGNX $15.36
  • GILT $8.05
  • Technical
  • Relative Strength Index (RSI)
  • RGNX 49.21
  • GILT 47.98
  • Support Level
  • RGNX $7.95
  • GILT $5.80
  • Resistance Level
  • RGNX $11.00
  • GILT $6.17
  • Average True Range (ATR)
  • RGNX 0.95
  • GILT 0.22
  • MACD
  • RGNX -0.10
  • GILT 0.01
  • Stochastic Oscillator
  • RGNX 28.52
  • GILT 70.13

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.

Share on Social Networks: